NCT03750981 C.A.P.A.B.L.E. (CrossFit® and Physical Activity: A Better Life Experience)
| NCT ID | NCT03750981 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Barbara Ann Karmanos Cancer Institute |
| Condition | Cancer Survivors |
| Study Type | INTERVENTIONAL |
| Enrollment | 500 participants |
| Start Date | 2018-11-12 |
| Primary Completion | 2027-11-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 500 participants in total. It began in 2018-11-12 with a primary completion date of 2027-11-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will introduce cancer survivors to cross-training with the expectation that the program proposed will ultimately result in superior improvements in functional performance, body composition and quality of life compared with the current American Cancer Society (ACS) guidelines for cancer survivors.
Eligibility Criteria
Inclusion Criteria: * Aged 18 years or older at time of program recruitment * Diagnosed with any cancer * Cleared from their physician to participate in the program (We assume that most patients will have completed treatment, however if a patient is currently under treatment, this should be their oncologist. If the patient is not currently undergoing treatment, this could be primary care physician or oncologist). * Available transportation to and from the facility on session days Exclusion Criteria * Widely metastatic cancers to the brain or bone may be excluded. * Patients using mobility assistance devices may be excluded. Exclusionary criteria will be reviewed on a case-by-case basis and patients with these limitations may be included with approval from Dr. Beebe-Dimmer and the referring physician.
Contact & Investigator
Jennifer Beebe-Dimmer, MPH, PhD.
PRINCIPAL INVESTIGATOR
Barbara Ann Karmanos Cancer Institute
Frequently Asked Questions
Who can join the NCT03750981 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cancer Survivors. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03750981 currently recruiting?
Yes, NCT03750981 is actively recruiting participants. Contact the research team at dimmerj@karmanos.org for enrollment information.
Where is the NCT03750981 trial being conducted?
This trial is being conducted at Detroit, United States.
Who is sponsoring the NCT03750981 clinical trial?
NCT03750981 is sponsored by Barbara Ann Karmanos Cancer Institute. The principal investigator is Jennifer Beebe-Dimmer, MPH, PhD. at Barbara Ann Karmanos Cancer Institute. The trial plans to enroll 500 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.